EXTH-50. DEVELOPMENT OF INVESTIGATOR INITIATED CLINICAL TRIAL OF TERT-TARGETING THERAPY USING ERIBULIN MESYLATE IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Despite of recent intense investigations, no effective molecular targeting therapy has been successfully developed in patients with glioblastomas (GBMs). Approximately 60–80% of GBM harbor mutations in the promoter region of telomerase reverse transcriptase (TERT), which leads to its upregulation. I...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Takahashi, Masamichi, Miki, Shunichiro, Fukuoka, Kohei, Maida, Yoshiko, Hayashi, Mitsuhiro, Hamada, Akinobu, Nishikawa, Ryo, Nagane, Motoo, Maruyama, Takashi, Mukasa, Akitake, Arakawa, Yoshiki, Arita, Hideyuki, Kitamura, Natsuko, Yonemori, Kan, Tamura, Kenji, Masutomi, Kenkichi, Narita, Yoshitaka, Ichimura, Koichi
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692632/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.342
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars